Published in Curr Opin Nephrol Hypertens on July 01, 2010
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant (2006) 2.20
PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol (2010) 2.19
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int (2009) 2.09
Differences between dialysis modality selection and initiation. Am J Kidney Dis (2012) 1.81
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant (2008) 1.81
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int (2005) 1.74
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol (2014) 1.41
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol (2003) 1.35
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther (2006) 1.33
Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol (2003) 1.33
Bone buffering of acid and base in humans. Am J Physiol Renal Physiol (2003) 1.23
Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol (2009) 1.21
Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens (2004) 1.11
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol (2005) 1.09
The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Invest (2009) 1.01
Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. J Bone Miner Res (2004) 1.00
Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol (2005) 0.99
Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant (2007) 0.99
Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int (2004) 0.97
Metabolic acidosis increases intracellular calcium in bone cells through activation of the proton receptor OGR1. J Bone Miner Res (2009) 0.97
Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr Opin Nephrol Hypertens (2008) 0.95
Sensitivity and specificity of 24-hour urine chemistry levels for detecting elevated calcium oxalate and calcium phosphate supersaturation. Can Urol Assoc J (2008) 0.95
Uric acid nephrolithiasis. Curr Rheumatol Rep (2007) 0.95
Quantitative trait loci for hypercalciuria in a rat model of kidney stone disease. J Am Soc Nephrol (2003) 0.95
Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. J Bone Miner Res (2003) 0.95
A form of Jansen's metaphyseal chondrodysplasia with limited metabolic and skeletal abnormalities is caused by a novel activating parathyroid hormone (PTH)/PTH-related peptide receptor mutation. J Clin Endocrinol Metab (2004) 0.94
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol (2012) 0.92
Sex modifies genetic effects on residual variance in urinary calcium excretion in rat (Rattus norvegicus). Genetics (2012) 0.91
Regulation of COX-2 mediates acid-induced bone calcium efflux in vitro. J Bone Miner Res (2007) 0.90
Elevated vitamin D receptor levels in genetic hypercalciuric stone-forming rats are associated with downregulation of Snail. J Bone Miner Res (2010) 0.90
Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am J Physiol Renal Physiol (2009) 0.90
The protein phosphatase calcineurin determines basal parathyroid hormone gene expression. Mol Endocrinol (2004) 0.90
Calcineurin Abeta is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol (2004) 0.88
Isolation and confirmation of a calcium excretion quantitative trait locus on chromosome 1 in genetic hypercalciuric stone-forming congenic rats. J Am Soc Nephrol (2006) 0.88
Smoking in dialysis patients: a systematic review and meta-analysis of mortality and cardiovascular morbidity. Am J Kidney Dis (2011) 0.88
When is it appropriate to order an ionized calcium? J Am Soc Nephrol (2008) 0.86
Idiopathic hypercalciuria. Curr Rheumatol Rep (2006) 0.86
Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength. J Bone Miner Res (2009) 0.86
Calcium and phosphorus homeostasis. Blood Purif (2009) 0.86
Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats. Am J Physiol Renal Physiol (2013) 0.86
Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification. PLoS One (2013) 0.85
Identification and characterization of cis-acting elements in the human and bovine PTH mRNA 3'-untranslated region. J Bone Miner Res (2004) 0.84
Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett (2002) 0.84
Human PTH gene regulation in vivo using transgenic mice. Am J Physiol Renal Physiol (2009) 0.83
RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. Am J Physiol Renal Physiol (2005) 0.83
The parathyroid hormone mRNA 3'-untranslated region AU-rich element is an unstructured functional element. J Biol Chem (2003) 0.82
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. Am J Physiol Renal Physiol (2009) 0.82
Cellular mechanisms of bone resorption induced by metabolic acidosis. Semin Dial (2003) 0.82
CKD-MBD: comfort in the trough of the U. Nephrol Dial Transplant (2011) 0.81
1,25(OH)₂D₃-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol (2013) 0.81
The calcium-sensing receptor regulates parathyroid hormone gene expression in transfected HEK293 cells. BMC Biol (2009) 0.81
Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial Int (2012) 0.80
Pharmacological inhibition of intracellular calcium release blocks acid-induced bone resorption. Am J Physiol Renal Physiol (2010) 0.80
Modeling hypercalciuria in the genetic hypercalciuric stone-forming rat. Curr Opin Nephrol Hypertens (2015) 0.78
Recurrent hypercalciuric nephrolithiasis--does diet help? N Engl J Med (2002) 0.78
Diuretics and disorders of calcium homeostasis. Semin Nephrol (2011) 0.78
Effect of metabolic and respiratory acidosis on intracellular calcium in osteoblasts. Am J Physiol Renal Physiol (2010) 0.77
Clinical application of calcium modeling in patients with chronic kidney disease. Nephrol Dial Transplant (2011) 0.77
Characterization of cis-acting element in renal NaPi-2 cotransporter mRNA that determines mRNA stability. Am J Physiol Renal Physiol (2002) 0.77
Making sense of the latest advice on vitamin D therapy. J Am Soc Nephrol (2011) 0.77
Cortisol inhibits acid-induced bone resorption in vitro. J Am Soc Nephrol (2002) 0.77
Micro-RNAs in the parathyroid: a new portal in understanding secondary hyperparathyroidism. Curr Opin Nephrol Hypertens (2016) 0.76
1,25(OH)₂D₃ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats. Calcif Tissue Int (2014) 0.76
Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD. Nephrol Dial Transplant (2011) 0.76
Mutational analysis of the PTH 3'-untranslated region in parathyroid disorders. Clin Endocrinol (Oxf) (2006) 0.76
The relation between bone and stone formation. Calcif Tissue Int (2012) 0.75
Vitamin D supplementation after renal transplantation: how much vitamin D should we prescribe? Kidney Int (2009) 0.75
Pathogenesis of parathyroid dysfunction in end-stage kidney disease. Pediatr Nephrol (2004) 0.75
Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol (2017) 0.75
The beehive and the merry-go-round in mineral metabolism. Curr Opin Nephrol Hypertens (2011) 0.75
An in silico method to predict net calcium transfer during hemodialysis. Conf Proc IEEE Eng Med Biol Soc (2017) 0.75
Nutritional vitamin D: the benefits of supplementation. Curr Opin Nephrol Hypertens (2008) 0.75
Innovations in bones and stones. Curr Opin Nephrol Hypertens (2013) 0.75
Bone disease in chronic kidney disease: unraveling the details. Curr Opin Nephrol Hypertens (2009) 0.75
Removing the paperwork from physical therapy. Healthc Inform (2011) 0.75
Bones and stones, edition 2015. Curr Opin Nephrol Hypertens (2015) 0.75
Mineral metabolism: confusion to clarity. Curr Opin Nephrol Hypertens (2012) 0.75
Something old, something new, something borrowed, something black. Curr Opin Nephrol Hypertens (2017) 0.75